TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA(TM) Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Stock Information for TScan Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TScan Therapeutics Inc.

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA(TM) Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Heme Development Strategy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.